2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilities
1997
Malaria morbidity in adults living in urban Burkina Faso.
Guiguemde T, Ouedraogo I, Ouedraogo J, Coulibaly S, Gbary A. Malaria morbidity in adults living in urban Burkina Faso. Medecine Tropicale 1997, 57: 165-8. PMID: 9304011.Peer-Reviewed Original ResearchConceptsLevel of immunizationPoor positive predictive valueSerious public health problemMain clinical featuresPublic health problemDiagnosis of malariaBobo-DioulassoPositive predictive valueParasitic indexMedian parasitemiaClinical featuresClinical symptomsMalaria morbidityProspective studyParasitological featuresParasite densityHigh incidencePlace of residencePredictive valueHealth problemsEndemic malariaMalariaUrban Burkina FasoAdultsMicroscopic examination